{"id":677,"date":"2026-02-07T04:23:22","date_gmt":"2026-02-07T04:23:22","guid":{"rendered":"https:\/\/kishiwada.tokushukai.or.jp\/en\/?page_id=677"},"modified":"2026-04-11T03:56:14","modified_gmt":"2026-04-11T03:56:14","slug":"neurology","status":"publish","type":"page","link":"https:\/\/kishiwada.tokushukai.or.jp\/en\/departments\/neurology\/","title":{"rendered":"Neurology"},"content":{"rendered":"<section class=\"op-section\">\n<div class=\"dept-when\">\n<div class=\"dept-when__block\">\n<h3 class=\"dept-when__title\">What we treat<\/h3>\n<ul class=\"dept-when__list\">\n<li>Memory concerns, MCI, and dementia evaluation<\/li>\n<li>Alzheimer&#8217;s-related testing \u2014 including <strong>amyloid PET<\/strong><\/li>\n<li>Disease-modifying treatment \u2014 <strong>Lecanemab<\/strong> and <strong>Donanemab<\/strong><\/li>\n<li>Epilepsy and seizure disorders<\/li>\n<li>Headache and dizziness<\/li>\n<li>Parkinson&#8217;s disease, stroke follow-up, peripheral nerve disorders<\/li>\n<\/ul><\/div>\n<div class=\"dept-when__block dept-when__block--er\">\n<h3 class=\"dept-when__title\">Key points<\/h3>\n<ul class=\"dept-when__list\">\n<li>Amyloid PET is available for selected patients<\/li>\n<li>Disease-modifying treatment for Alzheimer&#8217;s disease is available in eligible cases<\/li>\n<li>No waiting list \u2014 consultations are typically arranged promptly<\/li>\n<li>Second opinions are accepted<\/li>\n<\/ul>\n<p class=\"dept-when__note\">\n        Outpatient reception: Mon\u2013Sat, 8:00\u201311:30 AM<br \/>\n        Booking hours: Mon\u2013Sat, 8:00 AM\u20134:30 PM<br \/>\n        20 minutes from Kansai International Airport (KIX)\n      <\/p>\n<\/p><\/div>\n<\/p><\/div>\n<\/section>\n<section class=\"op-section\">\n<h2>About Us<\/h2>\n<p>\n    The Neurology Department at Kishiwada Tokushukai Hospital provides diagnosis and<br \/>\n    <strong>non-surgical treatment<\/strong> of conditions affecting the <strong>brain<\/strong>, <strong>spinal cord<\/strong>,<br \/>\n    <strong>peripheral nerves<\/strong>, and <strong>muscles<\/strong>.\n  <\/p>\n<p>\n    Patients commonly present with <strong>headache<\/strong>, <strong>numbness<\/strong>, or <strong>dizziness<\/strong>,<br \/>\n    as well as conditions such as <strong>stroke<\/strong>, <strong>Parkinson&#8217;s disease<\/strong>, <strong>epilepsy<\/strong>,<br \/>\n    and <strong>Alzheimer&#8217;s disease<\/strong>.\n  <\/p>\n<hr class=\"dept-about-minimal__divider\">\n<p>\n    Diagnostic evaluation may include <strong>amyloid PET<\/strong> when clinically indicated.<br \/>\n    Assessment for disease-modifying treatments such as<br \/>\n    <strong>Lecanemab (Leqembi\u00ae)<\/strong> and <strong>Donanemab (Kisunla\u00ae)<\/strong><br \/>\n    is performed in appropriate cases.\n  <\/p>\n<p>\n    If further investigation or treatment is required, referral to an appropriate facility is arranged,<br \/>\n    with follow-up coordinated as needed.\n  <\/p>\n<\/section>\n<section class=\"op-section\">\n<h2>When to visit \/ When to call ER<\/h2>\n<div class=\"dept-when\">\n<div class=\"dept-when__block\">\n<h3 class=\"dept-when__title\">Visit this department if:<\/h3>\n<ul class=\"dept-when__list\">\n<li>Headache or dizziness that is persistent or recurring<\/li>\n<li>Numbness or tingling in the hands or feet<\/li>\n<li>Unsteadiness while walking or frequent falls<\/li>\n<li>Loss of consciousness, fainting, or brief unresponsiveness<\/li>\n<li>Forgetfulness or difficulty organizing speech<\/li>\n<li>Double vision, drooping eyelids, slurred speech, or unusual facial movements<\/li>\n<li>Stiffness, slowed movement, tremor, or involuntary movements<\/li>\n<li>Memory concerns or suspected early dementia<\/li>\n<\/ul><\/div>\n<div class=\"dept-when__block dept-when__block--er\">\n<h3 class=\"dept-when__title\">Call ER immediately if:<\/h3>\n<ul class=\"dept-when__list\">\n<li>Sudden weakness or numbness of the face, arm, or leg (especially one side)<\/li>\n<li>Sudden difficulty speaking or understanding speech<\/li>\n<li>Sudden severe headache, confusion, or loss of consciousness<\/li>\n<li>Sudden vision loss, severe imbalance, or inability to walk<\/li>\n<li>Seizure lasting &gt;5 minutes, repeated seizures, or seizure with injury<\/li>\n<\/ul>\n<p class=\"dept-when__note\">\n        If stroke or another life-threatening condition is suspected, contact the Emergency Department immediately.\n      <\/p>\n<\/p><\/div>\n<\/p><\/div>\n<\/section>\n<section class=\"op-section\">\n<h2>Services<\/h2>\n<div class=\"dept-scope\">\n<div class=\"dept-scope-item\">\n      <a href=\"\/en\/departments\/neurology\/memory-dementia\/\" class=\"dept-scope-link\"><br \/>\n        Memory concerns and dementia evaluation<br \/>\n      <\/a>\n    <\/div>\n<div class=\"dept-scope-item\">\n      <a href=\"\/en\/departments\/neurology\/alzheimers-testing\/\" class=\"dept-scope-link\"><br \/>\n        Alzheimer&#8217;s-related testing (including amyloid PET)<br \/>\n      <\/a>\n    <\/div>\n<div class=\"dept-scope-item\">\n      <a href=\"\/en\/departments\/neurology\/leqembi\/\" class=\"dept-scope-link\"><br \/>\n        Lecanemab &amp; Donanemab \u2014 disease-modifying treatment<br \/>\n      <\/a>\n    <\/div>\n<div class=\"dept-scope-item\">\n      <a href=\"\/en\/departments\/neurology\/epilepsy\/\" class=\"dept-scope-link\"><br \/>\n        Epilepsy assessment and follow-up<br \/>\n      <\/a>\n    <\/div>\n<div class=\"dept-scope-item\">\n      <a href=\"\/en\/departments\/neurology\/headache-dizziness\/\" class=\"dept-scope-link\"><br \/>\n        Headache &amp; dizziness evaluation<br \/>\n      <\/a>\n    <\/div>\n<\/p><\/div>\n<div class=\"dept-services-note\">\n<p>\n      Appointments are required in principle.<br \/>\n      A referral letter is recommended but not mandatory.<br \/>\n      If available, please bring prior records (imaging reports, medication list, referral letter).\n    <\/p>\n<\/p><\/div>\n<\/section>\n<section class=\"op-section\" id=\"alzheimers\">\n<h2>Memory concerns and Alzheimer&#8217;s-related testing<\/h2>\n<div class=\"op-alert\">\n<div aria-hidden=\"true\">\u2139<\/div>\n<div>\n      Amyloid PET is not a general screening test.<br \/>\n      It is considered <strong>only when clinically indicated<\/strong><br \/>\n      (for example, in suspected early Alzheimer&#8217;s disease).\n    <\/div>\n<\/p><\/div>\n<p>\n    Memory concerns are evaluated through clinical history, cognitive testing, and imaging when appropriate.<br \/>\n    Amyloid PET may be used to assess amyloid plaque deposition when clinically indicated.\n  <\/p>\n<p style=\"color:#666;\">\n    Testing and treatment options depend on individual medical history and safety considerations.\n  <\/p>\n<\/section>\n<section class=\"op-section\" id=\"lecanemab\">\n<h2>Disease-modifying treatment: Lecanemab and Donanemab<\/h2>\n<p>\n    Lecanemab (Leqembi\u00ae) and Donanemab (Kisunla\u00ae) may be considered for selected patients with<br \/>\n    <strong>early Alzheimer&#8217;s disease<\/strong> or <strong>MCI due to Alzheimer&#8217;s disease<\/strong>.<br \/>\n    Eligibility is determined through specialist assessment and confirmatory testing (such as amyloid PET and MRI).\n  <\/p>\n<p style=\"color:#666;\">\n    Treatment protocols and monitoring requirements vary by case.\n  <\/p>\n<\/section>\n<section class=\"dept-leadership\">\n<h2 class=\"section-title\">Clinical leadership<\/h2>\n<p>\n    Neurology care is provided under clinical supervision within the department,<br \/>\n    with coordination across related specialties and emergency services when required.\n  <\/p>\n<p style=\"margin-top:10px;\">\n    <strong><a href=\"\/en\/about\/leadership\/makoto-izuta\/\">Makoto Izuta, M.D., Ph.D.<\/a><\/strong><br \/>\n    (Vice President) \u2014 Clinical Neurology \/ Certified Stroke Specialist\n  <\/p>\n<\/section>\n<section class=\"op-section\" id=\"contact\">\n<h2>Contact<\/h2>\n<div class=\"contact-cards\">\n<div class=\"contact-card contact-card--jmhc\">\n<div class=\"contact-card__eyebrow\">Patients from overseas<\/div>\n<h3 class=\"contact-card__title\">Contact us from overseas<\/h3>\n<p class=\"contact-card__lead\">\n        Start with a brief message to our International Medical Support Department.<br \/>\n        Please include your diagnosis, current condition, and the type of consultation or treatment you are seeking.<br \/>\n        We will review your case and guide you through the next steps.\n      <\/p>\n<ul class=\"ls-contact-icons\" style=\"margin-top:16px;\">\n<li>\n          <a href=\"https:\/\/lin.ee\/GRXNFOG\" class=\"ls-contact-icon ls-contact-icon--line\" target=\"_blank\" rel=\"noopener\"><br \/>\n            <i class=\"fa-brands fa-line\" aria-hidden=\"true\"><\/i><br \/>\n            <span class=\"sr-only\">LINE<\/span><br \/>\n          <\/a>\n        <\/li>\n<li>\n          <a href=\"https:\/\/wa.me\/818070945976\" class=\"ls-contact-icon ls-contact-icon--whatsapp\" target=\"_blank\" rel=\"noopener\"><br \/>\n            <i class=\"fa-brands fa-whatsapp\" aria-hidden=\"true\"><\/i><br \/>\n            <span class=\"sr-only\">WhatsApp<\/span><br \/>\n          <\/a>\n        <\/li>\n<li>\n          <a href=\"https:\/\/kishiwada.tokushukai.or.jp\/en\/contact.html\" class=\"ls-contact-icon ls-contact-icon--mail\" target=\"_blank\" rel=\"noopener\"><br \/>\n            <i class=\"fa-regular fa-envelope\" aria-hidden=\"true\"><\/i><br \/>\n            <span class=\"sr-only\">Online contact form<\/span><br \/>\n          <\/a>\n        <\/li>\n<\/ul>\n<p style=\"margin-top:14px;font-size:.92rem;\">\n        <a href=\"\/en\/international-treatment\/overview\/\">International Treatment Services \u2014 full details \u2192<\/a>\n      <\/p>\n<\/p><\/div>\n<div class=\"contact-card\">\n<div class=\"contact-card__eyebrow\">Patients living in Japan<\/div>\n<h3 class=\"contact-card__title\">Language support for patients in Japan<\/h3>\n<div class=\"contact-subblock contact-subblock--note\">\n<h4 class=\"contact-subblock__title\">Language support<\/h4>\n<ul class=\"contact-list\">\n<li>For treatment decisions and informed consent, <strong>professional medical interpretation<\/strong> is recommended.<\/li>\n<li>In-person interpretation can be arranged through JMHC.<\/li>\n<li>Remote interpretation (30+ languages) is also available via hospital-issued devices.<\/li>\n<\/ul><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/section>\n<p><script type=\"application\/ld+json\">\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@type\": \"MedicalWebPage\",\n  \"@id\": \"https:\/\/kishiwada.tokushukai.or.jp\/en\/departments\/neurology\/#medicalwebpage\",\n  \"name\": \"Neurology\",\n  \"description\": \"Neurology outpatient care for the diagnosis and non-surgical treatment of disorders of the brain, spinal cord, peripheral nerves, and muscles, including headache, dizziness, numbness, stroke follow-up, Parkinson's disease, epilepsy, and dementia evaluation. Alzheimer's-related testing such as amyloid PET, and disease-modifying treatment eligibility assessment, may be considered when clinically indicated.\",\n  \"inLanguage\": \"en\",\n  \"url\": \"https:\/\/kishiwada.tokushukai.or.jp\/en\/departments\/neurology\/\",\n  \"about\": [\n    { \"@type\": \"MedicalSpecialty\", \"name\": \"Neurology\" }\n  ],\n  \"author\": {\n    \"@type\": \"Organization\",\n    \"name\": \"Kishiwada Tokushukai Hospital\",\n    \"url\": \"https:\/\/kishiwada.tokushukai.or.jp\/\",\n    \"telephone\": \"+81-72-445-9915\"\n  }\n}\n<\/script><\/p>\n","protected":false},"excerpt":{"rendered":"<p>What we treat Memory concerns, MCI, and dementia evaluation Alzheimer&#8217;s-related testing \u2014 including amyloid PET Disease-modifying treatment \u2014 Lecanemab and Donanemab Epilepsy and seizure disorders Headache and dizziness Parkinson&#8217;s disease, stroke follow-up, peripheral nerve disorders Key points Amyloid PET is available for selected patients Disease-modifying treatment for Alzheimer&#8217;s disease is available in eligible cases No [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":264,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-677","page","type-page","status-publish","hentry"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/kishiwada.tokushukai.or.jp\/en\/wp-json\/wp\/v2\/pages\/677","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kishiwada.tokushukai.or.jp\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/kishiwada.tokushukai.or.jp\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/kishiwada.tokushukai.or.jp\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kishiwada.tokushukai.or.jp\/en\/wp-json\/wp\/v2\/comments?post=677"}],"version-history":[{"count":13,"href":"https:\/\/kishiwada.tokushukai.or.jp\/en\/wp-json\/wp\/v2\/pages\/677\/revisions"}],"predecessor-version":[{"id":1379,"href":"https:\/\/kishiwada.tokushukai.or.jp\/en\/wp-json\/wp\/v2\/pages\/677\/revisions\/1379"}],"up":[{"embeddable":true,"href":"https:\/\/kishiwada.tokushukai.or.jp\/en\/wp-json\/wp\/v2\/pages\/264"}],"wp:attachment":[{"href":"https:\/\/kishiwada.tokushukai.or.jp\/en\/wp-json\/wp\/v2\/media?parent=677"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}